, Volume 51, Issue 1, pp 7–11 | Cite as

The Importance of Dopamine D4 Receptors in the Action and Development of Antipsychotic Agents

  • Gavin P. Reynolds
Leading Article


The dopamine D4 receptor, recently identified by molecular biological techniques, is expressed in areas of the brain implicated in the pathophysiology of schizophrenia. Although it has a lower affinity than the D2 receptor for most antipsychotic drugs, the D4 receptor has a higher affinity for Clozapine, which may explain the unique efficacy of Clozapine in the treatment of schizophrenia. However, there is no association between genetic alterations of the D4 gene and either the development of schizophrenia or response to Clozapine administration, nor is the absence of the receptor related to major neuropsychiatric deficits. The report of an increase in D4 receptor density in the striatum in schizophrenia has not been consistently confirmed. Thus, it appears that there is little to support the development of D4 antagonists as potential antipsychotic agents.


Schizophrenia Clozapine Dopamine Receptor Antipsychotic Drug Raclopride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–9PubMedCrossRefGoogle Scholar
  2. 2.
    Farde L, Nordström AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and Clozapine. Arch Gen Psychiat 1992; 49: 538–44PubMedCrossRefGoogle Scholar
  3. 3.
    Owen F, Crow TJ, Poulter M, et al. Increased dopamine-receptor sensitivity in schizophrenia. Lancet 1978; 2: 223–5PubMedCrossRefGoogle Scholar
  4. 4.
    Mackay AVP, Iversen LL, Rossor M, et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiat 1982; 39: 991–7PubMedCrossRefGoogle Scholar
  5. 5.
    Reynolds GP, Riederer P, Jellinger K, et al. Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology 1981; 20: 1319–20PubMedGoogle Scholar
  6. 6.
    Wong DF, Wagner HN, Tune LE, et al. Positron emission tomography reveals elevated D-2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558–63PubMedCrossRefGoogle Scholar
  7. 7.
    Farde L, Wiesel F-A, Hall H, et al. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psych 1987; 44: 671–2CrossRefGoogle Scholar
  8. 8.
    Pilowsky LS, Costa DC, Ell PJ, et al. D2 receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. Br J Psychiat 1994; 164: 16–26CrossRefGoogle Scholar
  9. 9.
    Sokoloff P, Giros B, Martres M-P, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146–51PubMedCrossRefGoogle Scholar
  10. 10.
    Van Tol HHM, Bunzow JR, Guan H-C, et al. Cloning of the gene for human D4 receptor with high affinity for the antipsychotic Clozapine. Nature 1991; 350: 610–4PubMedCrossRefGoogle Scholar
  11. 11.
    Matsumoto M, Hidaka K, Tada S, et al. Full-length cDNA cloning and distribution of human dopamine D4 receptor. Mol Brain Res 1995; 29: 157–62PubMedCrossRefGoogle Scholar
  12. 12.
    Roberts GW. Schizophrenia: a neuropathological perspective. Br J Psychiat 1991; 158: 8–17CrossRefGoogle Scholar
  13. 13.
    Chabert C, Cavegn C, Bernard A, et al. Characterization of functional activity of dopamine ligands at human recombinant dopamine D4 receptors. J Neurochem 1994; 63: 62–5PubMedCrossRefGoogle Scholar
  14. 14.
    Fitton A, Heel RC. Clozapine. Drugs 1990; 40: 722–47PubMedCrossRefGoogle Scholar
  15. 15.
    Reynolds GP, Czudek C. New approaches to the drug treatment of schizophrenia. Adv Pharmacol 1995; 32: 461–503PubMedCrossRefGoogle Scholar
  16. 16.
    Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6: 602–8PubMedGoogle Scholar
  17. 17.
    Lahti RA, Evans DL, Stratman NC, et al. Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 1993; 236: 483–6PubMedCrossRefGoogle Scholar
  18. 18.
    Hidaka K, Matsumoto M, Tada S, et al. Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors. Neurosci Lett 1995; 186: 145–8PubMedCrossRefGoogle Scholar
  19. 19.
    Lawson CF, Mortimore RA, Schlachter SK, et al. Pharmacology of a human dopamine D4 receptor expressed in HEK293 cells. Meth Find Exp Clin Pharmacol 1994; 16: 303–7Google Scholar
  20. 20.
    Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2: 281–93Google Scholar
  21. 21.
    Van Tol HHM, Wu CM, Guan HC, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149–52PubMedCrossRefGoogle Scholar
  22. 22.
    Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to Clozapine. Lancet 1993; 341: 116PubMedCrossRefGoogle Scholar
  23. 23.
    Shaikh S, Collier D, Sham P, et al. Analysis of Clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Gen. In pressGoogle Scholar
  24. 24.
    Nanko S, Hattori M, Ikeda K, et al. Dopamine D4 receptor polymorphism and schizophrenia. Lancet 1993; 341: 689–90PubMedCrossRefGoogle Scholar
  25. 25.
    Sommer SS, Lind TJ, Heston LL, et al. Dopamine D4 receptor variants in unrelated schizophrenic cases and controls. Am J Med Gen 1993; 48: 90–3CrossRefGoogle Scholar
  26. 26.
    Seeman P, Ulpian C, Chouinard G, et al. Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. Am J Med Gen 1994; 54: 384–90CrossRefGoogle Scholar
  27. 27.
    Barr CL, Kennedy JL, Lichter JB, et al. Alleles at the dopamine D4 receptor do not contribute to the genetic susceptibility to schizophrenia in a large Swedish kindred. Am J Med Gen 1993; 48: 218–22CrossRefGoogle Scholar
  28. 28.
    Macciardi F, Petronis A, Van Tol HHM, et al. Analysis of the D-4 dopamine receptor gene variant in an Italian schizophrenia kindred. Arch Gen Psychiat 1994; 51: 288–93PubMedCrossRefGoogle Scholar
  29. 29.
    Nöthen MM, Cichon S, Hemmer S, et al. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Gen 1994; 3: 2207–12PubMedCrossRefGoogle Scholar
  30. 30.
    Seeman P, Guan H-C, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441–5PubMedCrossRefGoogle Scholar
  31. 31.
    Schoots O, Seeman P, Guan H-C, et al. Long-term haloperidol elevates dopamine D4 receptors by 2-fold in rats. Eur J Pharmacol 1995; 289: 67–72PubMedCrossRefGoogle Scholar
  32. 32.
    Murray AM, Hyde TM, Knable MB, et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995; 15: 2186–91PubMedGoogle Scholar
  33. 33.
    Reynolds GP, Mason SL. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 1994; 63: 1576–77PubMedCrossRefGoogle Scholar
  34. 34.
    Kessler RM, Whetsell WO, Ansari MS, et al. Identification of extrastriatal dopamine receptors in post mortem human brain with [125I]epidepride. Brain Res 1993; 609: 237–43PubMedCrossRefGoogle Scholar
  35. 35.
    Reynolds GP, Mason SL. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. Eur J Pharmacol 1995 Aug; 281: R5–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Gavin P. Reynolds
    • 1
  1. 1.Department of Biomedical ScienceUniversity of SheffieldSheffieldEngland

Personalised recommendations